Rates of death by any cause and a composite of myocardial infarction, stroke, and hospitalization for heart failure as recurrent events
Macdougall IC, et al.. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 2019; 380:447–458.
Rostoker G, Vaziri ND, Fishbane S. Iatrogenic iron overload in dialysis patients at the beginning of the 21st century. Drugs 2016; 76:741–757.
KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47:S11–S145.
Charytan DM, et al.. Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol 2015; 26:1238–1247.
Anker SD, et al.. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361:2436–2448.
Anker SD, et al.. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail 2018; 20:125–133.
Coyne, DW. Iron overload in dialysis patients: rust or bust? Kidney Int Rep 2017; 2:995–997.
Kapoian T, et al.. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008; 19:372–379.
Coyne DW. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18:975–984.